10 most valuable R&D projects in the pharmaceutical industry pipeline

EvaluatePharma, a data analytics firm focused on the pharmaceutical industry, released a list of the 10 most valuable research and development projects in the pharmaceutical industry pipeline.

Here are the top 10 most valuable projects in the pipeline — ranked by their net present value — as well as their estimated worldwide product sales in 2026:

1. Tirzepatide (Eli Lilly) — $2.2 billion
   
   
2. Inclisiran (Novartis) — $2 billion
   
   
3. Efgartigimod (argenx) — $2 billion
   
   
4. BMS-986165 (Bristol-Myers Squibb) — $1.8 billion
   
   
5. ALN-HBV02 (Vir Biotechnology) — $1.2 billion
   
   
6. Aducanumab (Biogen) — $1.6 billion
   
   
7. Belantamab (GlaxoSmithKline) — $1.3 billion
   
   
8. LN-144 (Iovance Biotherapeutics)  — $1.5 billion
   
   
9. AK002 (Allakos) — $1.2 billion
   
   
10. Risdiplam (Roche) — $1.4 billion